BeiGene Valuation

Is 49B undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 49B when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 49B (€13.8) is trading below our estimate of fair value (€40.11)

Significantly Below Fair Value: 49B is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 49B?

Key metric: As 49B is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 49B. This is calculated by dividing 49B's market cap by their current revenue.
What is 49B's PS Ratio?
PS Ratio6.2x
SalesCN¥23.51b
Market CapCN¥146.53b

Price to Sales Ratio vs Peers

How does 49B's PS Ratio compare to its peers?

The above table shows the PS ratio for 49B vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average7x
BIO3 Biotest
1.5x3.6%€1.4b
FYB Formycon
14x33.4%€848.4m
BAYN Bayer
0.4x1.0%€19.6b
HPHA Heidelberg Pharma
12x16.6%€102.1m
49B BeiGene
6.2x19.6%€20.2b

Price-To-Sales vs Peers: 49B is good value based on its Price-To-Sales Ratio (6.2x) compared to the peer average (7x).


Price to Sales Ratio vs Industry

How does 49B's PS Ratio compare vs other companies in the DE Biotechs Industry?

6 CompaniesPrice / SalesEstimated GrowthMarket Cap
CNW co.don
0.7xn/aUS$6.97m
V9Z Aceragen
0.4xn/aUS$3.12m
PA8 Paion
0.2x30.2%US$2.78m
V9Z Aceragen
0.3x-161.8%US$2.18m
49B 6.2xIndustry Avg. 8.0xNo. of Companies6PS0612182430+
6 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 49B is good value based on its Price-To-Sales Ratio (6.2x) compared to the European Biotechs industry average (8.1x).


Price to Sales Ratio vs Fair Ratio

What is 49B's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

49B PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio6.2x
Fair PS Ratio8.8x

Price-To-Sales vs Fair Ratio: 49B is good value based on its Price-To-Sales Ratio (6.2x) compared to the estimated Fair Price-To-Sales Ratio (8.8x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies